The ROBO-FISH consortium will develop and validate injection and imaging robots to automate oncology drug screening in zebrafish to mimic human disease.
Start – End dates: 01/04/21 – 31/03/24
Project reference: E!114899
Total budget: 3,349,547.88€
Co-financed by: Eurostars, Eureka EU & CDTI, Spain
¨This project has received funding from the Eurostars-2 joint programme with co-funding from CDTI and the European Union Horizon 2020 research and innovation programme.¨
Partners: Life Science Methods (Países Bajos), Confocal.nl (Países Bajos), Bioreperia (Suecia), Center for Molecular Medicine Norway (Norway)
Summary:
Over 10.000 compounds are screened for each approaved drug as it is still very difficult to predict the safety and efficacy of a drug candidate early in the drug discovery process. Zebrafish zenograft models are a promisisng solution, because they are small, inexpensive to keep and larvae are easy to manipualte and transparent, enabling screening of compunds on human tumours in context of a living organism. However, uptake is limited due to labour intensive workflows.
The ROBO-FISH consortium will develop and validate injection and imaging robots to automate oncology drug screening in zebrafish to mimic human disease. The robots will optimize sample handling and automate organ-specific injection and imaging, enabling high-throughput drug screening with zebrafish larvae. After the project, the validated ROBO-FISH workflow (injection robot and imaging robot) will be implemented at the Centre for Molecular Medicine Norway and CROs ZeClinics and BioReperia.